Life Sciences and Pharmaceutical M&A: Legal Guide

Life Sciences Deal Landscape and Target Classification

Life sciences M&A spans a broad range of transaction types, and the legal architecture of each deal depends heavily on where the target sits in the product development and commercialization continuum. Counsel must first characterize the target precisely before building a diligence framework or drafting representations and warranties. The categories are not academic. They drive which regulatory approvals are in scope, how purchase price is structured, and which closing conditions are realistic.

Platform companies hold enabling technology, drug delivery systems, or discovery infrastructure without a defined product set. These transactions are valued on platform potential and optionality. Diligence centers on IP ownership, freedom to operate, and whether the platform's capabilities can be independently validated. Regulatory approvals may be limited or absent, but manufacturing and data rights agreements with partners require careful mapping.

Clinical-stage acquisitions involve companies with one or more drug candidates in active IND-governed clinical trials, with no approved products generating revenue. Value is concentrated in the pipeline, in the IND itself, and in clinical data generated to date. Purchase price structures heavily weight contingent payments tied to regulatory milestones. Legal counsel must address IND transferability, trial continuity obligations, and the integrity of data that will support future NDA or BLA submissions.

Commercial-stage and specialty pharma acquisitions involve companies with at least one approved product generating revenue. These transactions require full FDA approval transfer mechanics, Medicaid rebate compliance review, manufacturing site analysis, and post-market commitment evaluation. The distinction matters operationally: a commercial product generates immediate cash flow obligations that platform and clinical assets do not. Specialty pharma roll-ups, in particular, introduce complexity around branded product exclusivity positions, generics competition exposure, and distribution channel management that must be assessed during diligence.

FDA Regulatory Framework and Approval Transfer Mechanics

The FDA regulatory framework governs how drug approvals, investigational applications, and manufacturing authorizations are transferred between entities in the context of an M&A transaction. The mechanics differ depending on the transaction structure and the regulatory status of the product at closing. Counsel advising on pharmaceutical transactions must understand the pathways and timelines associated with each type of transfer before the deal closes.

In a stock acquisition or merger where the target entity survives as a wholly owned subsidiary, FDA-regulated approvals typically remain with the entity and do not require immediate holder substitution. The acquiror becomes the controlling party but the regulated entity retains its approved applications. Subsequent integration decisions that consolidate regulatory functions, transfer manufacturing, or change the legal holder entity will require supplements and amendments depending on the nature of the change.

Asset purchases present a more complex regulatory picture. Each NDA, BLA, ANDA, and IND must be specifically identified in the asset schedule and transferred through the appropriate FDA filing pathway. There is no automatic vesting of FDA approvals in an asset purchase. A gap between closing and FDA's processing of a holder change application creates a period during which the seller technically remains the holder of record. Transition service agreements covering the regulatory holder function during this gap are standard and should be drafted with care to address liability, communication protocols, and post-market obligation compliance.

FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) each have specific procedures for processing holder substitution requests. The documentation requirements, review timelines, and points of contact differ between centers and between product types. Counsel should confirm early in the transaction which center has primary jurisdiction over each product and what the current submission requirements are, as FDA procedures are updated periodically.

NDA, BLA, and ANDA Holder Substitution Filings

The mechanics of substituting the holder of an approved NDA, BLA, or ANDA begin with a formal supplement filing. For NDAs and ANDAs, the acquiror submits a Prior Approval Supplement or a Changes Being Effected (CBE-30 or CBE-0) supplement depending on the nature and significance of the change. For BLAs, the process follows a similar supplement structure but may involve additional coordination with CBER given the biologics-specific manufacturing and potency considerations that accompany product transfer.

The supplement must identify the new holder, provide evidence of the legal basis for the transfer such as the executed purchase agreement or corporate merger documentation, confirm that manufacturing and quality arrangements are unchanged or describe the planned changes, and certify continued compliance with all post-market commitments and conditions of approval. FDA will review the submission and, if complete, approve the holder substitution, at which point the acquiror bears sole regulatory responsibility for the product.

For ANDAs in the generic drug context, holder substitution intersects with first-filer exclusivity rights, Paragraph IV certifications, and any pending patent litigation. The acquiror of a generic drug company must map each ANDA to its competitive status, including whether a 180-day exclusivity period is preserved, whether shared exclusivity arrangements exist, and whether any tentatively approved ANDAs remain subject to Paragraph IV 30-month stay constraints. The FTC has scrutinized reverse payment settlement agreements that the target entered prior to acquisition, and these agreements may impose ongoing obligations or limitations on the acquiror.

Orphan drug designations, fast track designations, and breakthrough therapy designations are not automatically transferred with the approval. The acquiror should confirm with FDA that all program designations are properly reflected in its name following holder substitution and request formal confirmation of designation status where relevant to the commercial or clinical strategy.

IND and CTA Transfer in Clinical-Stage Acquisitions

The Investigational New Drug application is the foundational regulatory instrument for clinical development in the United States. A sponsor holds an IND and bears responsibility for the safety and integrity of the clinical program conducted under it. When a clinical-stage company is acquired, the IND's status and transferability are among the most material regulatory considerations in the transaction.

FDA regulations at 21 CFR Part 312 permit the transfer of IND sponsorship through a written agreement between the transferring sponsor and the assuming sponsor. The new sponsor must submit an amendment to the IND notifying FDA of the change, providing the identity of the new sponsor, and confirming that the new sponsor accepts all obligations under the IND. There is no FDA approval required for the transfer itself, but the amendment must be filed and FDA must acknowledge receipt. The effective date of the transfer and the mechanics for ongoing safety reporting during the transition should be addressed precisely in both the acquisition agreement and the IND transfer amendment.

Clinical Trial Authorizations (CTAs) are the non-US equivalent of INDs, used in the European Union, United Kingdom, Canada, and other jurisdictions. Each CTA is issued by a national competent authority, and the transfer requirements differ by jurisdiction. An acquisition of a company conducting multi-national clinical trials may require CTA amendments in several jurisdictions simultaneously, each with independent timelines and documentation requirements. Counsel should map the trial geography early to identify which national filings are required and build this into the closing checklist and transition service agreement.

The acquiror also inherits the clinical site agreements, IRB approvals, and data safety monitoring board arrangements associated with the IND. Each of these relationships must be assessed for assignability, and novation agreements may be required at investigator sites that do not permit automatic assignment. A thorough IND transfer checklist covers regulatory filings, site contracts, data access, pharmacovigilance obligations, and protocol amendment history.

Contingent Value Rights (CVR) Structuring for Milestone and Sales Payments

Contingent value rights are contractual instruments used in pharmaceutical and life sciences M&A to bridge valuation gaps between buyers and sellers where a portion of the deal value depends on the occurrence of future events. These events are most commonly regulatory milestones such as NDA approval or priority review designation, clinical milestones such as completion of a Phase 3 trial or achievement of a primary endpoint, or commercial milestones such as reaching a defined annual net revenue threshold. CVRs allow sellers to participate in upside that buyers are unwilling to price into the upfront consideration.

The structural elements of a CVR include the milestone definitions, the payment amounts or formulas triggered by each milestone, the milestone achievement period, and the measurement and reporting obligations of the acquiror. The milestone definitions are the most heavily negotiated provisions. Sellers want definitions that reflect the scientific or commercial objectives clearly, that do not allow the acquiror to manipulate outcomes through expenditure decisions, and that include clear dispute resolution mechanisms. Acquirors want flexibility to make development and commercialization decisions without being constrained by CVR obligations that were calibrated to a prior owner's strategy.

The CVR agreement must address the acquiror's diligence obligations to pursue the milestone. Courts have interpreted implied covenants of good faith and fair dealing to impose minimum effort standards on acquirors even where express effort covenants are absent. Counsel should negotiate express commercially reasonable efforts or specific standard-of-care provisions and define what constitutes a breach. The CVR agreement should also address change of control of the acquiror post-closing, ensuring that successor obligations are binding.

CVRs may be structured as publicly traded instruments registered with the SEC or as private contractual rights. Publicly traded CVRs impose additional disclosure and securities law compliance obligations but provide sellers with liquidity. Private CVRs avoid SEC registration but require more robust contractual protections including audit rights, information rights, and enforcement mechanisms. The choice of structure has tax, securities, and corporate governance implications that should be assessed before the term sheet is finalized.

Purchase Price Allocation: Upfront, CVR, and Earnout Dynamics

Purchase price allocation in life sciences transactions is complicated by the coexistence of upfront cash, CVR obligations, and traditional earnouts. Each component receives different accounting and tax treatment, and the interaction between them must be addressed in the acquisition agreement, the CVR agreement, and the tax structuring analysis conducted by the parties.

For financial reporting purposes under ASC 805, the acquiror must allocate the total consideration including the estimated fair value of contingent consideration to the identifiable assets acquired and liabilities assumed. In a pharmaceutical acquisition, the primary intangible assets are approved product rights, in-process research and development (IPR&D), customer relationships, trade names, and favorable contracts. Each asset receives a fair value assignment that determines the amortization schedule and the tax basis going forward. IPR&D is expensed immediately for tax purposes under certain structures, creating temporary book-to-tax differences that affect the acquiror's financial statements for several years post-closing.

The initial fair value assigned to CVR instruments is based on probability-weighted cash flow models that discount expected milestone payments by the likelihood of achievement and the time value of money. These estimates require input from clinical development teams, market analysts, and regulatory consultants. Subsequent remeasurement of the CVR liability at each reporting date can create earnings volatility for the acquiror, which should be modeled as part of deal economics. Sellers and their advisors should understand that the accounting treatment of CVR fair value does not necessarily reflect what the acquiror is willing to pay in a negotiated settlement if a milestone dispute arises.

Section 1060 of the Internal Revenue Code governs asset purchase price allocation and requires both buyer and seller to allocate the total consideration among asset classes using the residual method. The parties' allocations must be consistent, and each party must file Form 8594 with its tax return for the year of acquisition. Disagreements about allocation, particularly with respect to Class VI intangibles such as patents and customer-based intangibles, can result in significant tax consequences and should be resolved in the acquisition agreement rather than left to post-closing negotiation.

Clinical Trial Diligence: Protocol Integrity, Site Management, Adverse Events

Diligence on an active clinical program is one of the most operationally intensive components of a clinical-stage pharmaceutical acquisition. The acquiror must assess not only the scientific validity of the program but the regulatory compliance and operational integrity of how the trials are being conducted. Deficiencies in clinical trial conduct can invalidate data, delay submissions, and trigger FDA warning actions that affect the acquiror's entire portfolio.

Protocol integrity review examines whether the trial is being conducted in accordance with the registered protocol, the approved IND, and applicable GCP standards. Significant protocol deviations, unauthorized amendments, or inconsistencies between the registered protocol and actual procedures are red flags. The acquiror's clinical team should review monitoring visit reports, audit reports, and data quality metrics for each active trial. Sites with elevated deviation rates or data query rates warrant additional scrutiny.

Site management assessment covers the number and geographic distribution of active investigator sites, the enrollment status and projected completion timelines, and whether any sites have received FDA inspection notices or been placed on partial or full clinical hold. The acquiror should confirm that investigator site agreements are current, that IRB approvals are active and not subject to pending renewals that could interrupt enrollment, and that principal investigators have not changed in ways that require protocol amendments or re-consenting of subjects.

Adverse event reporting is a critical compliance obligation. The acquiror must review whether all serious adverse events and unexpected safety findings have been reported to FDA within the required timeframes under 21 CFR 312.32. A pattern of late or missed safety reports can result in clinical hold, and unresolved safety questions can become FDA's basis for requesting additional data before accepting an NDA or BLA. The acquiror's pharmacovigilance team should conduct a retrospective review of safety reporting compliance before closing.

Hatch-Waxman Exclusivity, Orange Book Listings, and Paragraph IV Litigation

The Hatch-Waxman Act created the current framework for generic drug entry into the U.S. market and established the patent and exclusivity protections that branded pharmaceutical companies rely on to recoup development investment. Understanding the Hatch-Waxman landscape is essential in any transaction involving a branded pharmaceutical product with approved patents listed in FDA's Orange Book.

Orange Book listed patents are those that the NDA holder has certified cover the approved product's compound, formulation, or method of use. Acquirors of branded NDA products assume responsibility for the accuracy of Orange Book listings and must update them if new patents issue or existing patents expire. Inaccurate or overly broad Orange Book listings have attracted FTC enforcement attention, and the acquiror should review existing listings for compliance with FDA's current guidance on listable patents.

Paragraph IV certifications are filed by ANDA applicants who challenge one or more listed patents as invalid or not infringed. The NDA holder and patent owner must receive notice of the certification and have 45 days to file suit. If suit is filed, a 30-month stay of final ANDA approval takes effect, giving the branded company additional time to litigate. When an acquiror purchases an NDA product that is subject to pending Paragraph IV litigation, it steps into the role of the plaintiff and must assess the strength of the patents at issue, the litigation posture, and the economics of settlement.

First-filer exclusivity under Hatch-Waxman grants the first ANDA applicant to file a substantially complete Paragraph IV certification a 180-day period of market exclusivity against other generic entrants. This exclusivity can be extraordinarily valuable and is sometimes the primary asset being acquired in a generic company transaction. The acquiror must confirm that the exclusivity right is intact, that no forfeiture events have occurred or are imminent, and that the exclusivity period has not been triggered and partially consumed. Shared exclusivity scenarios, where multiple filers have Paragraph IV certifications accepted on the same day, require additional analysis.

BPCIA Biosimilar Exclusivity and Reference Product Transfer

The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the Affordable Care Act, established a regulatory pathway for biosimilar and interchangeable biologic products. For acquirors of reference product sponsors, the BPCIA exclusivity framework is a material asset requiring careful analysis. Reference product sponsors hold a 12-year period of regulatory exclusivity from the date of first licensure during which FDA may not approve a biosimilar based on the reference product's data.

The BPCIA patent dance is a complex pre-litigation information exchange process between the biosimilar applicant and the reference product sponsor. The process involves sequential disclosure of the biosimilar's manufacturing process and the reference product sponsor's patents, followed by a negotiation of which patents to litigate in a first round and which to hold in reserve. Acquirors of reference product sponsors inherit the patent dance position, including any ongoing first-round litigation and the risk that the reference product sponsor has taken positions in the dance that constrain the acquiror's future litigation strategy.

When a BLA for a reference product is transferred in an acquisition, the 12-year exclusivity period runs from the original approval date, not the transfer date. Acquirors should map the exclusivity expiry date for each reference product in the portfolio and assess what biosimilar applications are pending or anticipated. The commercial and pricing strategy for the reference product in the years preceding exclusivity expiry may be substantially different from the strategy appropriate during the protected period.

Interchangeability designation under BPCIA is a higher standard than biosimilarity alone and permits pharmacists to substitute the biosimilar for the reference product without a prescriber's intervention. Whether the target holds a reference product that faces interchangeable biosimilar competition or whether the target holds a biosimilar seeking interchangeability designation has material implications for the competitive and regulatory landscape assessment.

FTC Pharma Second Requests and Divestiture Remedy Design

Pharmaceutical and life sciences transactions above the Hart-Scott-Rodino (HSR) filing thresholds are subject to mandatory pre-merger notification and a waiting period during which the FTC and DOJ may request additional information. In the pharmaceutical sector, the FTC has jurisdiction over the substantial majority of significant transactions and applies a product-market analysis that is granular to the indication, mechanism of action, and competitive substitutability of the products at issue.

A Second Request is issued when the reviewing agency determines that it needs additional information to assess competitive effects. Second Requests in pharmaceutical transactions are among the most document-intensive in any industry, covering clinical development files, commercial forecasts, competitive analyses, marketing materials, and communications about the strategic rationale for the acquisition. Companies should have experienced HSR counsel managing the Second Request response from the moment the request is received. Substantive compliance with a Second Request can take three to nine months depending on the volume of documents and the complexity of the competition analysis.

Where the FTC identifies a product overlap in a relevant market, it will seek a remedy that restores competition. In pharmaceutical transactions, the preferred remedy is divestiture of a complete product package including the NDA, manufacturing rights, customer relationships, and clinical data needed for the acquiror to become an independent competitor. The FTC has moved away from accepting licensing arrangements as adequate remedies in recent years. Remedy negotiations with the FTC require coordination between antitrust counsel, regulatory counsel, and business development teams to identify viable divestiture packages and acceptable buyers.

State AG and European Commission Review of Life Sciences Transactions

Federal HSR clearance is necessary but not sufficient for pharmaceutical transactions with a multi-jurisdictional footprint. State attorneys general retain independent authority to challenge mergers under state antitrust laws, and several states have been active participants in pharmaceutical merger review, particularly where transactions affect access to drugs in markets with concentrated pharmacy distribution or where price effects are anticipated for state Medicaid programs.

State AG investigations can proceed in parallel with FTC review or after federal clearance is granted. States may seek injunctive relief or negotiate separate consent agreements that require divestitures or behavioral commitments beyond what the FTC has required. Counsel advising on transactions with significant state-level exposure should engage state AG offices early, particularly in states with activist antitrust programs such as California, New York, and Massachusetts. The state review timeline should be factored into the deal timeline and the conditions to closing.

European Commission merger review under the EU Merger Regulation applies to transactions above the specified turnover thresholds. For pharmaceutical transactions, the Commission's review mirrors the FTC's product-market analysis but applies its own precedents and remedy preferences. Transactions that require both FTC and EC review must manage parallel investigation timelines, separate document productions, and the risk that one regulator's remedy demands affect the overall deal economics in ways that the other regulator's analysis did not anticipate. Coordinating the antitrust narrative across jurisdictions while respecting each regulator's procedural requirements is a specialized capability that should be retained before pre-merger filings are submitted.

Other jurisdictions with mandatory merger notification requirements for pharmaceutical transactions include the United Kingdom's CMA, Canada's Competition Bureau, China's SAMR, and Brazil's CADE. Each has independent thresholds, timelines, and analytical frameworks. The global regulatory calendar for significant life sciences transactions now routinely spans twelve to eighteen months, and the deal structure, including the break fee framework, must account for this timeline realistically.

Medicaid Rebate Compliance and 340B Orphan Drug Exclusions

Manufacturers of covered outpatient drugs who seek Medicaid reimbursement must enter into a Medicaid Drug Rebate Agreement (MDRA) with the Centers for Medicare and Medicaid Services (CMS). The MDRA obligates the manufacturer to pay quarterly rebates to state Medicaid programs based on the product's Average Manufacturer Price (AMP) and Best Price. Acquirors of pharmaceutical companies with Medicaid-reimbursed products assume all obligations under existing MDRAs and must notify CMS of the change in ownership.

AMP and Best Price calculations are among the most complex compliance obligations in the pharmaceutical industry. The definitions of which transactions are included or excluded in these calculations are the subject of ongoing regulatory guidance, litigation, and government enforcement actions. An acquiror performing pre-closing diligence must review the target's AMP and Best Price calculation methodologies, assess whether existing policies comply with current CMS guidance, and identify any pending government investigations or qui tam actions related to rebate calculations. Incorrect calculations can result in retroactive rebate obligations that materially affect the value of the acquired business.

The 340B program requires covered manufacturers to sell covered outpatient drugs to eligible covered entities at or below the 340B ceiling price, which is calculated based on the product's AMP and Medicaid rebate percentage. The 340B orphan drug exclusion permits manufacturers to exclude orphan drugs from 340B pricing obligations when dispensed at certain covered entity types. This exclusion has been the subject of regulatory and litigation activity in recent years. Acquirors of drugs that carry an orphan designation should assess whether the orphan drug exclusion is currently operative, whether the covered entity types to which it applies are properly identified, and whether there are pending HRSA enforcement actions related to the target's 340B compliance.

DEA Registration Transfer and Controlled Substance Activities

Drug manufacturers, distributors, dispensers, and researchers who handle Schedule I through V controlled substances must hold a current DEA registration for each activity and location. DEA registrations are not transferable and do not survive a change in business ownership in the same way that other permits might. When a pharmaceutical company is acquired, the acquiror must apply for its own DEA registration for each controlled substance activity it intends to continue, and these applications must be filed in advance of closing if continuity of controlled substance operations is required.

The DEA registration application process requires the applicant to identify the activities for which registration is sought, the schedules of controlled substances involved, and the physical location of the registered activity. DEA conducts a pre-registration inspection for most new manufacturer and distributor registrations, and the inspection timeline adds a variable to the deal schedule that counsel must anticipate. If the acquiror is not able to obtain DEA registration before closing, a transition arrangement with the seller may be necessary, but DEA does not recognize informal transfer arrangements and the legal risk of unregistered controlled substance activity is severe.

In a stock acquisition where the target continues to exist as a separate legal entity, the DEA registration remains with the entity and does not require immediate action at closing. Integration decisions that involve merging the controlled substance activities into the acquiror's existing registration structure require a separate DEA regulatory analysis and likely additional applications and inspections. Companies with active DEA registrations for Schedule I research activities, such as those involved in psychedelic or cannabis-derived drug development, face additional DEA scrutiny and longer processing timelines that should be factored into the integration plan.

The acquiror should also conduct a thorough review of the target's suspicious order monitoring (SOM) program and diversion control procedures. DEA has increased its enforcement focus on SOM compliance in recent years, and deficiencies in this area can result in registration suspension or revocation that interrupts manufacturing and distribution operations. Pre-closing diligence should include a review of DEA inspection history, any outstanding 82-series forms filed with DEA, and whether the target has received any administrative inspection warrants or letters of admonishment.

Manufacturing Transfer: cGMP Compliance, EMA/PMDA Transitions

The transfer of pharmaceutical manufacturing operations is a regulatory event that requires coordination between FDA, EMA, PMDA, and other applicable health authorities depending on the markets in which the product is approved. Manufacturing site changes for approved products require prior approval supplements in the United States, Type II variations in the European Union, and comparable major variation filings in Japan. Each of these filings has its own timeline, data requirements, and inspection implications.

cGMP compliance is a threshold issue. FDA may not approve a manufacturing site change supplement if the receiving site has outstanding cGMP compliance issues, and the agency's pre-approval inspection of the new site can delay approval if deficiencies are identified. Acquirors should assess the cGMP compliance status of both the target's existing manufacturing sites and any sites to which manufacturing will be transferred post-closing. A review of FDA inspection history, EMA GMP certificates, and any Form 483 observations or Warning Letters issued within the past five years is a minimum diligence requirement.

Technology transfer is the operational process by which manufacturing knowledge, procedures, and specifications are conveyed from one site to another. A well-documented technology transfer package includes the master batch record, in-process specifications, stability protocols, analytical method validations, and process validation data. Gaps in this documentation are a common discovery in pharmaceutical acquisitions, particularly in transactions involving smaller companies that have not maintained documentation to the standard required for a multi-site or post-acquisition manufacturing environment. The cost and time to reconstruct missing documentation should be assessed as part of deal economics.

For products sold in both the United States and the European Union, the acquiror must identify the Marketing Authorization Holder (MAH) for EU purposes and ensure that the MAH change process is completed in each member state where the product is approved. In the post-Brexit environment, a separate UK Medicines and Healthcare products Regulatory Agency (MHRA) variation is required for the United Kingdom. Japan's PMDA requires its own regulatory variation for manufacturing site changes, and the submission must be in Japanese with Japan-specific data requirements. The global regulatory calendar for a full manufacturing transfer of a multi-market product routinely spans eighteen to twenty-four months.

Post-Closing Integration: Commercial, Regulatory, and Pharmacovigilance

Post-closing integration in a pharmaceutical acquisition is more complex than in most other industries because the regulatory obligations do not pause during the integration period. FDA-regulated activities must continue without interruption, and the acquiror's assumption of these obligations begins at closing regardless of whether the integration plan is complete. A well-structured integration plan addresses commercial, regulatory, and pharmacovigilance functions in parallel from day one.

Commercial integration encompasses the transfer of customer contracts, specialty pharmacy agreements, co-pay assistance programs, and managed care contracts. Each of these arrangements has change of control provisions that may require notice or consent from the counterparty. The acquiror's commercial team should complete a contract-by-contract review of the target's commercial agreements before closing and develop a day-one communication plan for key accounts, specialty distributors, and payer contacts. Disruptions in distribution relationships during the integration period can cause material revenue losses that are difficult to attribute to any single cause post-closing.

Regulatory integration requires the acquiror to assume responsibility for all post-market commitments associated with the acquired product. These commitments, which may include required pediatric studies, post-marketing safety studies, and risk evaluation and mitigation strategy (REMS) program administration, are legally binding conditions of approval. Failure to fulfill post-market commitments can result in FDA enforcement action including warning letters, civil monetary penalties, and withdrawal proceedings. The acquiror must identify all outstanding commitments at closing, assign internal ownership, and build the required activities into the product development and regulatory affairs budget.

Pharmacovigilance integration is among the most time-sensitive post-closing obligations. The acquiror must establish or confirm that adverse event collection, processing, and reporting systems are operational for the acquired products from the moment of closing. Expedited safety reports for serious, unexpected adverse events must be submitted to FDA within seven or fifteen calendar days depending on the severity and expectedness classification. Annual Periodic Adverse Drug Experience Reports (PADERs) or Development Safety Update Reports (DSURs) must be filed on schedule. A pharmacovigilance transition plan that is agreed between the parties before closing, tested against actual case volumes, and staffed with qualified personnel is a non-negotiable integration requirement in any pharmaceutical acquisition.

---

Life Sciences and Pharmaceutical M&A: Frequently Asked Questions

---

Related Resources